Form 4: 10x Genomics Director Sridhar Kosaraju Granted 15,357 Restricted Stock Units

10x Genomics, Inc. Director Sridhar Kosaraju has been granted 15,357 Class A Common Stock Restricted Stock Units (RSUs) as part of his compensation, vesting quarterly from May 21, 2025.

Summary

• Sridhar Kosaraju, a Director of 10x Genomics, Inc. (TXG), acquired 15,357 shares of Class A Common Stock on June 3, 2025, in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0, indicating they are part of a compensation package.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs will vest in quarterly installments, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025, contingent on Mr. Kosaraju's continued service as a provider.
• Following this transaction, Sridhar Kosaraju directly beneficially owns 56,449 shares of Class A Common Stock.
• Additionally, 3,000 shares of Class A Common Stock are indirectly beneficially owned through the Kosaraju Family Trust dated June 21, 2014, where Mr. Kosaraju serves as trustee.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders and is a standard form of compensation, indicating continued commitment.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

The future outlook for Sridhar Kosaraju's equity holdings includes the quarterly vesting of 15,357 Restricted Stock Units, commencing from May 21, 2025, subject to his continued service as a director.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all industries, where directors and executives receive equity-based compensation to align their incentives with company performance.

Related Party Transactions

• Sridhar Kosaraju indirectly holds 3,000 shares of Class A Common Stock through the Kosaraju Family Trust dated June 21, 2014, of which he is the trustee. This is a pre-existing arrangement and not a new transaction.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially leading to decisions that enhance shareholder value.
• Employees: While not directly impacting general employees, such compensation structures for leadership can signal stability and long-term strategic focus.

Next Steps

• The RSUs will vest in quarterly increments, with the first vesting occurring three months after May 21, 2025, and subsequent vestings every three months thereafter, provided the reporting person continues as a service provider.

Key Dates

Keywords

10x Genomics, TXG, Sridhar Kosaraju, Restricted Stock Units, RSU, Insider Transaction, Form 4, Beneficial Ownership, Equity Compensation, Director Compensation